Références utilisées pour le contenu de cette section

1. GINA. Global Strategy for Asthma Management and Prevention 2020 [Guideline international en asthme 2020]. Available from: https://ginasthma.org.
2.  Aaron SD, Boulet LP, Reddel HK, Gershon AS. Underdiagnosis and Overdiagnosis of Asthma. Am J Respir Crit Care Med. 2018;198(8):1012-20.
3. Fuchs O, Bahmer T, Rabe KF, von Mutius E. Asthma transition from childhood into adulthood. Lancet Respir Med. 2017;5(3):224-34.
4. J.M. FitzGerald CL, M.D. Lougheed et al. Recognition and management of severe asthma : A Canadian Thracic Society position statement. Canadian journal of respiratory, critical care, and sleep medicine. 2017;1:199–221.
5. Toskala E, Kennedy DW. Asthma risk factors. Int Forum Allergy Rhinol. 2015;5 Suppl 1(Suppl 1):S11-6.
6. DictionnaireMedical.fr. Atopie 2015 [Available from: https://www.dictionnaire-medical.fr/definitions/696-atopie/.
7. Kuruvilla ME, Lee FE, Lee GB. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clin Rev Allergy Immunol. 2019;56(2):219-33.
8. GINA. Difficult-to-treat & severe asthma in adolescent and adult patients – Diagnosis And Management 2019 [updated April 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf.
9. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18(5):716-25.
10. Boulet LP, Boutin H. L’asthme : Comment devenir expert de la prise en charge de cette maladie: Les Presses de l’Université Laval; 2016.
11. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. Front Pediatr. 2019;7:246.
12. GINA. Guide de poche pour le traitement et la prévention de l’asthme 2019 [updated 2019. Available from: https://ginasthma.org/wp-content/uploads/2019/09/GINA-2019-main-Pocket-Guide-French-wms.pdf.
13. Connie L. Yang EAH, Patrick Mitchell, Joe Reisman, Delanya Podgers, Kathleen M. Hayward, Mark Waite, and Clare D. Ramsey. 2021 Canadian Thoracic Society Guideline – A focused update on the management of very mild and mild asthma. CANADIAN JOURNAL OF RESPIRATORY, CRITICAL CARE, AND SLEEP MEDICINE. 2021.
14. InformedHealth.org. Non-drug interventions for asthma: IQWiG; 2008 [updated 30 novembre 2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279518/?report=reader#_NBK279518_pubdet_.
15. RQESR. INFO RQESR – Le Rapport GINA 2019. In: RQER, editor. 2019.
16. RQESR. INFO RQESR – GINA 2017 : Quoi de neuf? In: RQESR, editor. 2017.
17. BoehringerIngelheimCanada. Monographie de produit : Spiriva, Respimat. 2019.
18. NovartisPharmaCanada. Monographie de produit – Xolair 2015 [updated 25 février 2015. Available from: https://www.novartis.ca/sites/www.novartis.ca/files/xolair_scrip_f.pdf.
19. GSK. Monographie de produit – Nucala 2020 [updated 12 mars 2020. Available from: https://ca.gsk.com/media/1319657/nucala.pdf.
20. TevaCanada. Product monograph – Cinqair 2017 [updated 15 mars 2017. Available from: https://pdf.hres.ca/dpd_pm/00038484.PDF.
21. AstraZeneca. Monographie – Fasenra 2020 [updated 10 février 2020. Available from: https://www.astrazeneca.ca/content/dam/az-ca/frenchassets/Ourmedicines/fasenra-product-monograph-fr.pdf.
22. Inc. S-aC. Monographie – Dupixent 2019 [updated 25 septembre 2019. Available from: http://products.sanofi.ca/fr/dupixent-fr.pdf.
23. Corren J, Parnes JR, Wang L, Mo M, Roseti SL, Griffiths JM, et al. Tezepelumab in Adults with Uncontrolled Asthma. N Engl J Med. 2017;377(10):936-46.
24. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med. 2000;343(5):332-6.
25. Pfizer. Découvrez les 5 dimensions de l’adhésion thérapeutique et les 4 principes fondamentaux de l’optimisation des médicaments 2018 [updated Avril 2018. Available from: https://www.pfizerpro.lu/public/news/découvrez-les-5-dimensions-de-l’adhésion-thérapeutique-et-les-4-principes-fondamentaux?destination=public/news/découvrez-les-5-dimensions-de-l’adhésion-thérapeutique-et-les-4-principes-fondamentaux.